Increased Soluble PD-1 Predicts Response to Nivolumab plus Ipilimumab in Melanoma
Authors:
- Jesper Geert PedersenJPJesper Geert Pedersen
- Mateo SokacMSMateo Sokac
- Boe Sandahl SørensenBSBoe Sandahl Sørensen
- Adam Andrzej LuczakALAdam Andrzej Luczak
- Ninna Aggerholm-PedersenNANinna Aggerholm-Pedersen
- Nicolai Juul BirkbakNBNicolai Juul Birkbak
- Trine Heide ØllegaardTØTrine Heide Øllegaard
- Martin Roelsgaard JakobsenMJMartin Roelsgaard Jakobsen
Open Access
Abstract
Background: Checkpoint inhibitors have revolutionized the treatment of metastatic melanoma, yielding long-term survival in a considerable proportion of the patients. Yet, 40–60% of patients do not achieve a long-term benefit from such therapy, emphasizing the urgent need to identify biomarkers that can predict response to immunotherapy and guide patients for the best possible treatment. Here, we exploited an unsupervised machine learning approach to identify potential inflammatory cytokine signatures from liquid biopsies, which could predict response to immunotherapy in melanoma. Methods: We studied a cohort of 77 patients diagnosed with unresectable advanced-stage melanoma undergoing treatment with first-line nivolumab plus ipilimumab or pembrolizumab. Baseline and on-treatment plasma samples were tested for levels of PD-1, PD-L1, IFNγ, IFNβ, CCL20, CXCL5, CXCL10, IL6, IL8, IL10, MCP1, and TNFα and analyzed by Uniform Manifold Approximation and Projection (UMAP) dimension reduction method and k-means clustering analysis. Results: Interestingly, using UMAP analysis, we found that treatment-induced cytokine changes measured as a ratio between baseline and on-treatment samples correlated significantly to progression-free survival (PFS). For patients treated with nivolumab plus ipilimumab we identified a group of patients with superior PFS that were characterized by significantly higher baseline-to-on-treatment increments of PD-1, PD-L1, IFNγ, IL10, CXCL10, and TNFα compared to patients with worse PFS. Particularly, a high PD-1 increment was a strong individual predictor for superior PFS (HR = 0.13; 95% CI 0.034–0.49; p = 0.0026). In contrast, decreasing levels of IFNγ and IL6 and increasing levels of CXCL5 were associated with superior PFS in the pembrolizumab group, although none of the cytokines were individually predictors for PFS. Conclusions: In short, our study demonstrates that a high increment of PD-1 is associated with superior PFS in advanced-stage melanoma patients treated with nivolumab plus ipilimumab. In contrast, decreasing levels of IFNγ and IL6, and increasing levels of CXCL5 are associated with response to pembrolizumab. These results suggest that using serial samples to monitor changes in cytokine levels early during treatment is informative for treatment response.Keywords
Funding Information
- Kræftens Bekæmpelse (R167-A10737-17-S2, R246-A14695, R238-2016-2708)
- Lundbeck Foundation (R167-A10737-17-S2, R246-A14695, R238-2016-2708)
- Danish Kræftforskningsfond (R167-A10737-17-S2, R246-A14695, R238-2016-2708)
- The Danish Health Authority “Empowering cancer immunotherapy in Denmark” (R167-A10737-17-S2, R246-A14695, R238-2016-2708)
- from Aarhus University Graduate School, Faculty of Health (R167-A10737-17-S2, R246-A14695, R238-2016-2708)
This publication has 33 references indexed in Scilit:
- Immunological correlates of treatment and response in stage IV malignant melanoma patients treated with IpilimumabOncoImmunology, 2016
- Genomic correlates of response to CTLA-4 blockade in metastatic melanomaScience, 2015
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In VivoThe Journal of Immunology, 2015
- Genetic Basis for Clinical Response to CTLA-4 Blockade in MelanomaNew England Journal of Medicine, 2014
- PD-1 blockade induces responses by inhibiting adaptive immune resistanceNature, 2014
- Multiplex Cytokine Concentration Measurement: How Much Do the Medium and Handling Matter?Mediators of Inflammation, 2013
- Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell ResponseMolecular Therapy, 2013
- Effect of anticoagulants on multiplexed measurement of cytokine/chemokines in healthy subjectsCytokine, 2012
- Enhancement of Vaccine-induced Primary and Memory CD8+ T-cell Responses by Soluble PD-1Journal of Immunotherapy, 2011
- Soluble PD-1 Facilitates 4-1BBL–Triggered Antitumor Immunity against Murine H22 Hepatocarcinoma In vivoClinical Cancer Research, 2007